With Ph3 da­ta, Pfiz­er wants to have the ‘first and on­ly’ RSV vac­cine to cov­er adults as young as 18 years old

The race for RSV vac­cine mar­ket dom­i­nance con­tin­ues with Pfiz­er re­port­ing on Tues­day that Abrys­vo passed its reg­is­tra­tional test in at-risk peo­ple aged 18 to 59 years.

Al­though GSK has al­ready sub­mit­ted its bid for Arexvy’s la­bel ex­pan­sion in adults aged 50 to 59 years, a reg­u­la­to­ry win for Pfiz­er in adults as young as 18 years would make Abrys­vo the “first and on­ly” vac­cine to do so in this pop­u­la­tion. Both vac­cines are al­ready FDA-ap­proved in old­er adults aged 60 years and up, with GSK dom­i­nat­ing the mar­ket so far.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.